Sublingual buprenorphine spray
The invention provides sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides sublingual formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.
1. A sublingual spray formulation comprising:
buprenorphine, a pharmaceutically acceptable salt thereof or a derivative thereof is at an amount from about 0.08% to about 1.3% w/w;
water as a solvent is at an amount from about 38% to about 40% w/w;
a cosolvent consisting of a mixture of ethanol in an amount of 55% w/w and propylene glycol in an amount of about 5% w/w;
an antioxidant consisting of a mixture of butylated hydroxyanisole (BHA) in an amount of about 0.01% w/w and butylated hydroxytoluene (BHT) in an amount of about 0.005% w/w; and
menthol at an amount of about 0.05% w/w,
wherein w/w denotes weight by total weight of the formulation.
2. The sublingual spray formulation of claim 1 that is capable of producing a droplet size distribution wherein greater than 98% of the composition particles are greater than 10 microns in diameter during administration.
3. The sublingual spray formulation of claim 1 that is capable of producing a droplet size distribution wherein:
the mean Dv(10) is from about 10 to about 30 microns during administration;
the mean Dv(50) is from about 30 to about 80 microns during administration; and
the mean Dv(90) is from about 80 to about 200 microns during administration.
4. The sublingual spray formulation of claim 1 that is capable of producing a spray span ((Dv90−Dv10)/Dv50) of from about 1.2 to about 3.3.
5. The sublingual spray formulation of claim 1 that is capable of producing a spray plume that has an ovality ratio of from about 1.1 to 2.4.
6. The sublingual spray formulation of claim 1 that is capable of producing a spray plume width that is from about 25 to about 45 millimeters during administration and a spray plume angle that is from about 30 to about 55 degrees during administration.
7. The sublingual spray formulation of claim 1 that is capable of producing a D(4,3) of 55 to 95 microns.
8. The sublingual spray formulation of claim 1 that is capable of producing a droplet size distribution wherein the C max (ng/mL) of buprenorphine is from about 0.6 to about 0.8 following administration.
9. The sublingual spray formulation of claim 1 that is capable of producing a droplet size distribution wherein the T max of buprenorphine is from about 1.5 to about 1.9 hours following administration.
10. A method of treating pain comprising administering the sublingual spray formulation of claim 1 to a patient in need thereof.
11. A method of treating opioid dependence comprising administering the sublingual spray formulation of claim 1 to a patient in need thereof.